Literature DB >> 17573861

Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model.

Konstantin Kotliar1, Mathias Maier, Svetlana Bauer, Nikolaus Feucht, Chris Lohmann, Ines Lanzl.   

Abstract

PURPOSE: Intravitreal injections are used extensively to treat retinal diseases. Performing an intravitreal injection increases intraocular volume by the amount of fluid brought into the eye. Whether this influences intraocular pressure (IOP) was investigated here.
METHODS: A biomechanical model relying on 3-dimensional elasticity theory was developed to determine the short-term effect of volume changes on IOP. We calculated the effect for intravitreal injections of 0.1 ml in myopic, emmetropic and hyperopic eyes. Our calculations were compared with IOP measurements obtained immediately after intravitreal injection of 4 mg triamcinolone in 0.1 ml solution (IVTA) in 22 patients. Shortly after the measurement had been taken, IOP was reduced by paracentesis.
RESULTS: Immediately after IVTA, measured IOP was elevated by a mean of 40.6 +/- 12.1 mmHg compared with initial pressure (p < 0.001). Measured and calculated IOP were comparable. Eyes with shorter axial length had higher IOP immediately after the injection (p < 0.05).
CONCLUSIONS: The effect of injected volumes on IOP can be calculated with a biomechanical model. Our results show that paracentesis might be recommended when injecting 0.1 ml of a substance to avoid a short-term increase in IOP. As intravitreal injections are mostly applied in diseases that are due to vascular compromise, it might be prudent not to impair perfusion in those eyes, even for short periods of time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573861     DOI: 10.1111/j.1600-0420.2007.00939.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  19 in total

1.  Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle.

Authors:  Katrin Lorenz; Isabella Zwiener; Alireza Mirshahi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-21       Impact factor: 3.117

Review 2.  [Intravitreal injection. Monitoring to avoid postoperative complications].

Authors:  C H Meyer; F Ziemssen; H Heimann
Journal:  Ophthalmologe       Date:  2008-02       Impact factor: 1.059

3.  Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF.

Authors:  M Gómez-Mariscal; B Puerto; F J Muñoz-Negrete; V de Juan; G Rebolleda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-06-28       Impact factor: 3.117

4.  Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients.

Authors:  C D Murray; D Wood; V Allgar; G Walters; R P Gale
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

5.  Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.

Authors:  Matthew D Karl; Jasmine H Francis; Saipriya Iyer; Brian Marr; David H Abramson
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2017-01-17       Impact factor: 1.402

6.  Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide.

Authors:  Gul Arikan; Ali Osman Saatci; Ferit Hakan Oner
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

7.  Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection.

Authors:  Sehnaz Ozcaliskan; Faruk Ozturk; Pelin Yilmazbas; Ozlem Beyazyildiz
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

8.  Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length.

Authors:  Andrea Cacciamani; Francesco Oddone; Mariacristina Parravano; Fabio Scarinci; Marta Di Nicola; Giorgio Lofoco
Journal:  Jpn J Ophthalmol       Date:  2012-10-24       Impact factor: 2.447

Review 9.  Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration.

Authors:  Joanne D Du; Wye-Khay Fong; Suzanne Caliph; Ben J Boyd
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

10.  [Management of a ruptured globe].

Authors:  A Viestenz; W Schrader; M Küchle; S Walter; W Behrens-Baumann
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.